Peptide

TesamorelinStudienlage & Dosis

Zugelassen für HIV-assoziierte Lipodystrophie — viszerale Fettreduktion.

Studienlage in Zahlen

Studien gesamt: 82
Mit Abstract: 49
Meta / Systematic / RCT: 2
Häufig zitiert: 33
Erscheinungsjahre: 1993–2026

Tesamorelin im Kontext von Peptide

Dieses Thema ist Teil unserer Welt „Peptide". Dort findest du Methodik, Studienlage und Hebel mit dem größten Effekt — sowie die Reihenfolge, in der sich Hebel sinnvoll aufeinander aufbauen.

Zur Welt Peptide

Top-Studien zu Tesamorelin

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases
Physiology202680 einflussreiche Zitationen
Growth hormone (GH) is secreted by the anterior pituitary gland under the control of hypothalamic neuroendocrine neurons that express somatostatin or growth hormone-releasing hormone (GHRH). Ghrelin, originating primarily in the stomach,…
Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection.
The Journal of clinical endocrinology and metabolism199379 einflussreiche Zitationen
Body wasting, characterized by disproportionate loss of body cell mass, is a feature of many chronic diseases, including infection with the human immunodeficiency virus (HIV). Therapies that merely increase energy intake do not…
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.
The Journal of clinical endocrinology and metabolism2021n=61B73 einflussreiche Zitationen
Growth hormone (GH) and IGF-1 help regulate hepatic glucose and lipid metabolism, and reductions in these hormones may contribute to development of nonalcoholic fatty liver disease (NAFLD). To assess relationships between hepatic…
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.
Therapeutics and clinical risk management202349 einflussreiche Zitationen
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease without any approved treatment to-date despite intensive research efforts by researchers and pharmaceutical industry. Fibroblast growth factor (FGF)-21 has been gaining…
Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.
Frontiers in endocrinology202444 einflussreiche Zitationen
Growth hormone (GH) is the key regulator of insulin-like growth factor I (IGF-I) generation in healthy states. However, portal insulin delivery is also an essential co-player in the regulation of the GH/IGF-I axis by affecting and…
Growth hormone and aging: a clinical review.
Frontiers in aging2025n=152D32 einflussreiche Zitationen
Aging is a complex biological process characterized by functional decline, reduced quality of life, and increased vulnerability to diseases such as type 2 diabetes, cardiovascular conditions, neurodegeneration, and cancer. Advances in…
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
The lancet. HIV2019n=61B30 einflussreiche Zitationen
Non-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population. We assessed the effects of tesamorelin on liver fat…
Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease.
Clinical endocrinology2021n=10326 einflussreiche Zitationen
Background Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in young adults with obesity. Obesity is associated with relative growth hormone (GH) deficiency, and data from animal studies and from humans with pituitary GH…
GHRH in diabetes and metabolism.
Reviews in endocrine & metabolic disorders2025D26 einflussreiche Zitationen
Despite over a century of insulin therapy and recent advances in glucose monitoring, diabetes and its complications remain a significant burden. Current medications are not durable, with symptoms often returning after treatment ends, and…
Growth hormone-releasing hormone receptor (GHRH-R) and its signaling.
Reviews in endocrine & metabolic disorders2025D26 einflussreiche Zitationen
The hypothalamic polypeptide growth hormone-releasing hormone (GHRH) stimulates the secretion of growth hormone (GH) from the pituitary through binding and activation of the pituitary type of GHRH receptor (GHRH-R), which belongs to the…

Weitere Themen in Peptide

Peptide-Überblick

Peptide, BPC-157, TB-500, Sicherheit und Studienlage.

Verabreichung

Subkutan, intramuskulär, nasal, oral, topisch — Bioverfügbarkeit und Sicherheit.

Autoimmunitäts-Risiko

Immun-Modulation kann sowohl Toleranz fördern als auch entgleisen lassen.

BPC-157

Peptid für Geweberegeneration, Heilung und sportliche Erholung.

Cerebrolysin

Schweinehirn-Peptid-Mix, Schlaganfall-Studien, in DE unzugelassen.

CJC-1295

GHRH-Analog, Halbwertszeit-Varianten und Pulse-Patterns.

Dihexa

Angiotensin-Derivat, kognitive/Neuroplastizitäts-Hinweise im Tiermodell.

GHK-Cu

Kupfer-Peptid für Hautgesundheit, Anti-Aging und Wundheilung.

GHRP-2

GH-Releaser, älter, Appetit-Stimulation als Nebeneffekt.

GHRP-6

GH-Releaser mit starker Appetit-Komponente.

Rebound nach GLP-1

Gewichtszunahme nach Absetzen ohne Lifestyle-Anker.

GLP-1 Nebenwirkungen

Übelkeit, Magenentleerung, Muskelverlust, Pankreatitis-Risiko.

Hexarelin

GH-Releaser, Toleranz-Aufbau schnell, kardiale Hinweise.

IGF-1 LR3

Modifiziertes IGF-1 mit langer Halbwertszeit — Hypertrophie, Krebsrisiko-Debatte.

Immune Modulation

Automatisch via Trend Scout entdeckt. Supplements targeting inflammation and immune resilience remain a central research area.. PubMed: 11956 Ergebnisse.

Injektionssicherheit

Sterile Technik, BAC-Wasser, Hautdesinfektion — medizinisches Thema.

Ipamorelin

Selektiver GH-Releaser, Cortisol-Sparing und Stack-Kombinationen.

KPV

Alpha-MSH-Fragment — entzündungshemmend, Darm, Haut, frühe Forschung.

Liraglutid

Erste GLP-1-Generation für Diabetes/Adipositas — täglich, niedrigere Effektgröße.

LL-37

Antimikrobielles Peptid, Wundheilung, Immun-Modulation, frühe Forschung.